Back to Education and Resources
HSDD (Hypoactive Sexual Desire Disorder)
Front MatterWebcastDownload SlidesPostTest/Evaluation
Why Not? How to Incorporate Female Sexual Medicine into Your Busy Practice (Dr Rubin) and Treatments for Low Sexual Desire with Associated Distress in Pre and Postmenopausal Women (Dr Simon).
with James A. Simon, MD, CCD, NCMP, IF, FACOG and Rachel Rubin, MD


OB/GYNs, urologists, primary care physicians, endocrinologists, nurses with focus in reproductive/sexual medicine, NPs/PAs, psychiatrists, psychologists/sex therapists, residents/fellows of above disciplines, managed care clinicians, and clinical pharmacists interested in management and treatment of hypoactive sexual desire disorder (HSDD).


Sexual health is an integral component of women’s psychological and overall physical health. Clinicians often perceive the treatment of female sexual health as a quality of life issue and low health priority; furthermore, they often do not believe they possess the knowledge and experience to diagnose and manage HSDD. Even though HSDD significantly impairs their overall sense of well-being, sexual satisfaction, and the quality of their relationships, many patients do not bring up sexual health, due to embarrassment and lack of education on sexual health. Physicians often feel inadequately trained to directly address sexual health and unable to focus on patient concerns due to time-constraints. There is a clear need for education to help clinicians proactively speak to patients about sexual health concerns that patients may consider difficult to discuss, and to facilitate collaboration between specialists in various disciplines that manage women’s health.


At the conclusion of this activity participants should be better able to:

  1. Identify HSDD through screening questionnaires, assessment, and physical examination
    • Ensure proper diagnosis/successful treatment outcomes
  2. Recognize level of distress HSDD has on each patient’s overall health/well-being
  3. Encourage each provider to ask
    • Discuss sexual health with all patients, to determine “normal” sexual function/dysfunction for her
  4. Select appropriate treatment based on FDA-approved options, patient’s goals, and degree to which patient wants sexual function restored
  5. Evaluate and proactively manage AEs of HSDD medications to allay patient concerns and ensure adherence to treatment


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Learning Collaborative (GLC) and CogniMed Inc. GLC is accredited by the ACCME to provide continuing medical education for physicians.

GLC designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


To resolve identified/potential conflicts of interest, the educational content was fully reviewed by a member of GLC Clinical Content Review Committee who has no financial relationships with commercial interests. The resulting certified activity was found to provide educational content that is current, evidence based and balanced.


In accordance with ACCME Standards for Commercial Support, GLC requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

Sean Barrett has nothing to disclose.
Barry A. Fiedel, PhD has nothing to disclose.

CogniMed Inc.
Jeffrey Rosenberg has nothing to disclose.

Dr Rubin is research support for AbbVie, Bayer and IPSEN. She has consulted for Sprout.

Dr. Simon receives fees for advisory boards/consultations from AbbVie, Inc., AMAG Pharmaceuticals, Inc., Bayer HealthCare Pharmaceuticals Inc., CEEK Enterprises, LLC, Covance Inc., Dare´ Bioscience, Duchesnay USA, Hologic Inc., KaNDy/NeRRe Therapeutics Ltd., Mitsubishi Tanabe Pharma Development America, Inc., Shionogi Inc., Sprout2 Inc., and TherapeuticsMD. He receives speaking fees from AbbVie, Inc., AMAG Pharmaceuticals, Inc., Duchesnay USA, and TherapeuticsMD. He receives fees for grants/research from AbbVie, Inc., Bayer Healthcare LLC, Endoceutics, Inc., GTx, Inc., Ipsen, Myovant Sciences, ObsEva SA, TherapeuticsMD, and Viveve Medical. He is also a stock shareholder in Sermonix Pharmaceuticals.

Off-label statement
Off label statement provided: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of CogniMed Inc. or GLC. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive on the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely on the information contained within this educational activity.

Jointly provided by

Funded by an independent Educational Grant from AMAG.

Next to Webcast